Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about CNO: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
CNO is a concept in neurodegeneration research. Key relationships include: activates, regulates, inhibits. Associated with ALS, Aging, Als. Connected to 61 entities in the SciDEX knowledge graph.
| Name | CNO |
| Key Genes/Proteins | ANXIETY |
| Related Diseases | Als, Anxiety, Addiction, Cancer, Aging |
Knowledge base pages for this entity
graph TD
CNO["CNO"]
CNO -->|"target for"| Cancer["Cancer"]
CNO -->|"target for"| Aging["Aging"]
CNO -->|"target for"| Ms["Ms"]
CNO -->|"target for"| Als["Als"]
CNO -.biomarker for.-> Inflammation["Inflammation"]
CNO -->|"target for"| Dementia["Dementia"]
CNO -->|"target for"| Anxiety["Anxiety"]
CNO -->|"target for"| Alzheimer["Alzheimer"]
CNO -->|"regulates"| Schizophrenia["Schizophrenia"]
h_e3506e5a["h-e3506e5a"] -->|"targets"| CNO
PER["PER"] -->|"activates"| CNO
CANCER["CANCER"] -->|"activates"| CNO
INFLAMMATION["INFLAMMATION"] -.biomarker for.-> CNO
GSR["GSR"] -->|"inhibits"| CNO
ANXIETY["ANXIETY"] -->|"inhibits"| CNO
DEMENTIA["DEMENTIA"] -->|"inhibits"| CNO
PARKINSON_S_DISEASE["PARKINSON'S DISEASE"] -->|"regulates"| CNO
PARKINSON["PARKINSON"] -->|"regulates"| CNO
AND["AND"] -->|"inhibits"| CNO| Target | Relation | Type | Str |
|---|---|---|---|
| Als | activates | disease | 0.75 |
| Anxiety | inhibits | disease | 0.75 |
| Addiction | regulates | disease | 0.65 |
| Cancer | therapeutic_target | disease | 0.65 |
| Aging | therapeutic_target | disease | 0.65 |
| Ms | therapeutic_target | disease | 0.65 |
| Als | therapeutic_target | disease | 0.65 |
| Inflammation | biomarker_for | disease | 0.65 |
| Dementia | therapeutic_target | disease | 0.65 |
| Anxiety | therapeutic_target | disease | 0.65 |
| Alzheimer | therapeutic_target | disease | 0.65 |
| Ms | regulates | disease | 0.65 |
| Schizophrenia | regulates | disease | 0.65 |
| Parkinson | regulates | disease | 0.65 |
| Aging | regulates | disease | 0.65 |
| Als | regulates | disease | 0.65 |
| Cancer | regulates | disease | 0.65 |
| Inflammation | associated_with | disease | 0.65 |
| Anxiety | activates | disease | 0.65 |
| Dementia | activates | disease | 0.65 |
| Aging | activates | disease | 0.65 |
| ALS | activates | disease | 0.65 |
| Cancer | activates | disease | 0.65 |
| ALS | inhibits | disease | 0.65 |
| Dementia | inhibits | disease | 0.65 |
| Alzheimer | inhibits | disease | 0.65 |
| Amyotrophic Lateral Sclerosis | activates | disease | 0.65 |
| Neurodegeneration | inhibits | disease | 0.65 |
| GSR | therapeutic_target | gene | 0.60 |
| GSR | activates | gene | 0.60 |
| Dopamine Signaling | regulates | pathway | 0.60 |
| neurodegeneration | implicated_in | disease | 0.60 |
| Rb | therapeutic_target | protein | 0.60 |
| Rb | regulates | protein | 0.60 |
| neurodegeneration | protects_against | disease | 0.60 |
| neuroinflammation | inhibits | disease | 0.60 |
| NOX2 | protects_against | gene | 0.60 |
| NOX2 | activates | gene | 0.60 |
| neurodegeneration | activates | disease | 0.60 |
| FUS | activates | gene | 0.60 |
| PER | regulates | gene | 0.60 |
| CANCER | activates | gene | 0.60 |
| PER | activates | gene | 0.60 |
| INFLAMMATION | biomarker_for | gene | 0.60 |
| DEMENTIA | inhibits | gene | 0.60 |
| PARKINSON'S DISEASE | regulates | gene | 0.60 |
| PARKINSON | regulates | gene | 0.60 |
| AMYOTROPHIC LATERAL SCLEROSIS | activates | gene | 0.60 |
| AND | biomarker_for | gene | 0.60 |
| AND | associated_with | gene | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| h-e3506e5a | targets_gene | hypothesis | 0.90 |
| h-e3506e5a | targets | hypothesis | 0.80 |
| ANXIETY | inhibits | gene | 0.70 |
| GSR | inhibits | gene | 0.60 |
| GSR | therapeutic_target | gene | 0.60 |
| PER | activates | gene | 0.60 |
| CANCER | activates | gene | 0.60 |
| INFLAMMATION | biomarker_for | gene | 0.60 |
| DEMENTIA | inhibits | gene | 0.60 |
| PARKINSON'S DISEASE | regulates | gene | 0.60 |
| PARKINSON | regulates | gene | 0.60 |
| NEURODEGENERATION | inhibits | gene | 0.60 |
| ALS | activates | gene | 0.60 |
| AND | biomarker_for | gene | 0.60 |
| AND | inhibits | gene | 0.60 |
| AND | associated_with | gene | 0.60 |
| PER | therapeutic_target | gene | 0.60 |
| ANXIETY | therapeutic_target | gene | 0.60 |
| DEMENTIA | therapeutic_target | gene | 0.60 |
| BDNF | activates | gene | 0.55 |
| BMAL1 | debate_co_mention | gene | 0.45 |
| CLOCK | debate_co_mention | gene | 0.45 |
| BMAL1 | co_discussed | gene | 0.40 |
| PLIN2 | co_discussed | gene | 0.40 |
| G3BP1 | co_discussed | gene | 0.40 |
| TUBB3 | co_discussed | gene | 0.40 |
| CLOCK | co_discussed | gene | 0.40 |
| CLOCK | co_associated_with | gene | 0.40 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Synthetic Biology Rewiring via Orthogonal Receptors | 0.420 | neurodegeneration | Microglia-astrocyte crosstalk amplificat |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.521
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Current and future advances in practice: SAPHO syndrome and chronic non-bacteria [PMID:39411288] | Furer V, Kishimoto M, Tomita T, Elkayam | Rheumatol Adv Pract | 2024 | 1 |
| NMR-based isotopic and isotopomic analysis. [PMID:33198965] | Akoka S, Remaud GS | Prog Nucl Magn Reson Spectrosc | 2020 | 1 |
| Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid n [PMID:32632286] | Nagai Y, Miyakawa N, Takuwa H, Hori Y, O | Nat Neurosci | 2020 | 1 |
| Modulating Dopamine Signaling and Behavior with Chemogenetics: Concepts, Progres [PMID:30814274] | Runegaard AH, Fitzpatrick CM, Woldbye DP | Pharmacol Rev | 2019 | 1 |
| The Utilization of Robotic Pets in Dementia Care. [PMID:27716673] | Petersen S, Houston S, Qin H, Tague C, S | J Alzheimers Dis | 2017 | 1 |
| Chemogenetic Modulation of Astrocytic Activity Rescues Hippocampus Associated Ne [PMID:41089460] | ["Gerasimov E", "Berg M", "Bolshakova A" | Neural plasticity | 2025 | 0 |
| Chemogenetic Tools and their Use in Studies of Neuropsychiatric Disorders. [PMID:38957949] | Neřoldová M, Stuchlík A | Physiological research | 2024 | 0 |
| Clozapine-N-oxide protects dopaminergic neurons against rotenone-induced neuroto [PMID:38182072] | Sun Q, Wang Y, Hou L, Li S, Hong JS, Wan | Free radical biology & medicin | 2024 | 0 |
| Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice. [PMID:36892930] | ["Traut J", "Mengual J", "Meijer E", "Mc | eLife | 2023 | 0 |
| To Be or No B2: A Rare Cause of Stridor and Weakness in a Toddler. [PMID:34395718] | ["Frederick A", "Yang J", "Schneider S", | Child neurology open | 2021 | 0 |
| Fragment Database FDB-17. [PMID:28375006] | Visini R, Awale M, Reymond JL | Journal of chemical informatio | 2017 | 0 |
| Clozapine metabolites protect dopaminergic neurons through inhibition of microgl [PMID:27184631] | ["Jiang L", "Wu X", "Wang S", "Chen S", | Journal of neuroinflammation | 2016 | 0 |